Executive SummaryThree years ago, Lilly gambled big on managed care with its acquisition of PCS--and lost. Its new strategy wagers almost as much on research, but this time the bets are hedged. As it aggressively builds infrastructure, it expands its program but limits its own flexibility and diminishes the likelihood that it can exploit all of its programs. Thus it will increasingly outlicense and sell assets it is not exploiting.
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.